U.S. Markets open in 5 hrs 39 mins

Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?

ALLISON GATLIN
Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?

Alnylam Pharmaceuticals stock slipped Wednesday as investors questioned the safety of its rare-disease drug, dubbed givosiran, in a late-stage test of patients with acute hepatic porphyria.